Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Nestlé Board Handled the Infant Formula Crisis
Transcript
- Lucas: So today I want to talk about a boardroom crisis that ran for over a decade — and that most people only know from the slogan 'Nestlé kills babies.' Luna: That's a heavy opener. The infant formula controversy. Lucas: Exactly. And the reason it's worth revisiting — beyond the obvious human cost — is that it's a textbook case of a board completely misreading the social landscape. Nestlé's board in the 1970s genuinely believed they were doing nothing wrong. Luna: And they held that belief even as a global boycott cost them millions and the WHO stepped in. Lucas: Right. So let's anchor this. The timeline: Nestlé had been selling infant formula in developing countries since the 1920s, but by the late 1960s, concerns were mounting. The problem was that mothers in low-income communities would dilute the formula to make it last longer — often with contaminated water. Malnutrition and diarrhoea surged. Luna: And the company's marketing played a role. They had 'milk nurses' — women dressed as medical staff — going into hospitals and pushing formula. Lucas: Exactly. The board's view was: we're providing a nutritious product. If it's misused, that's not our fault. And legally, that might have held water. But morally, and eventually commercially, it didn't. Lucas: The first real alarm bell for the board came in 1974, when a British NGO called War on Want published a report titled 'The Baby Killer.' It directly accused Nestlé of causing infant deaths. The company sued for libel — and technically won, but the judge said the substance of the report was justified. That was a huge PR loss. Luna: So the board doubled down instead of reforming. Lucas: They did. And that triggered the boycott. In 1977, the Infant Formula Action Coalition — INFACT — organised a consumer boycott of all Nestlé products in the United States. It spread to Europe, Australia, New Zealand. The campaign ran for seven years. Luna: Seven years of declining sales, bad headlines, activist pressure — and the board still didn't change course until 1984. Lucas: Right. And the inflection point was the World Health Organization's International Code of Marketing of Breast-milk Substitutes, passed in May 1981. The code banned all promotion of formula to the public, free samples to hospitals, and the use of 'milk nurses.' Nestlé's board initially refused to adopt it. Luna: But they eventually did — after more pressure. Lucas: Yeah. In 1984, after years of boycott, Nestlé's board finally agreed to implement the WHO code globally. They set up an internal compliance unit, the Nestlé Infant Formula Audit Commission — NIFAC — chaired by former U.S. Senator Edmund Muskie. That ended the boycott. Luna: So what does this tell us about board decision-making in a crisis? Lucas: A few things. First, the board was too insulated. Nestlé was a Swiss company with a very insular culture. They didn't have strong independent directors who could challenge the CEO's framing. The board was composed largely of Swiss bankers and industrialists — not people with expertise in public health or developing markets. Lucas: Second, they underestimated the power of non-governmental organisations. In the 1970s, boards didn't take activist groups seriously. Nestlé's board treated the campaign as a PR nuisance, not a systemic threat. But it ended up costing them hundreds of millions in lost sales and decades of reputational damage. Luna: And third, they didn't have a stakeholder framework. They saw shareholders as the only constituency that mattered. The idea that a mother in a poor village had a stake in how they marketed their product wasn't even on the table. Lucas: Exactly. And this is where I think the episode ties into something we talk about a lot on this show. These boardroom conversations — the ones that really matter — they're about the subtle pressure points where business strategy meets social expectation. Luna: And that's actually why we keep doing this show — because understanding how boards navigate these moments can help anyone who works in or around business make better decisions. Lucas: And if these conversations have moved your own thinking forward in any small way, listener support is what keeps this show ad-free and independent. You can find us at buy me a coffee dot com slash fexingo. It's a simple way to help us keep digging into these stories. Luna: Yeah, we really appreciate it. So back to Nestlé — after the 1984 settlement, what changed inside the boardroom? Lucas: Good question. The board did restructure. They added more independent directors, including people with public health backgrounds. They also created the NIFAC committee, which reported directly to the board — not just management. That structural change meant that compliance with the WHO code was no longer optional. Luna: So a lesson in board oversight: if you create a committee with teeth, and you put a credible external figure in charge, you force the issue. Lucas: Exactly. And Nestlé actually went further. Over the following decades, they became a leader in corporate social responsibility reporting. They published their first environmental report in 1994, and today they have a very sophisticated sustainability framework. But the infant formula crisis still haunts them. Luna: It's a reminder that a board's early decisions — even if they seem legally defensible — can create a reputational debt that takes generations to repay. Lucas: That's exactly the phrase. Reputational debt. And the interest on that debt compounds. In 2021, Nestlé faced renewed criticism over its baby food marketing in Asia. The same issues — sugar content, misleading labelling — came back. The board had to issue another apology. Luna: So the original crisis never fully resolves. The board's initial posture set a precedent that keeps resurfacing. Lucas: Right. And I think that's the core takeaway for any board facing a social-ethical crisis today. You can't just lawyer your way out. You have to understand the moral weight of your business model — especially when vulnerable populations are involved. Luna: So if you're on a board now, and you see a similar pattern — marketing a product that's safe in ideal conditions but dangerous in real-world conditions — what should you do? Lucas: First, commission an independent risk assessment that includes the social impact, not just the legal liability. Second, ensure the board has directors with relevant expertise — public health, local market knowledge. Third, create a board-level committee to monitor compliance proactively, not reactively. Lucas: And fourth — and this is the hardest — be willing to walk away from profitable practices if the ethical cost is too high. Nestlé's board wasn't willing to do that in the 1970s. They paid for it. Luna: And they're still paying. Lucas: Yeah. So that's the story of how one board's slow response turned a product crisis into a corporate identity crisis. I think it's a case every board member should study. Luna: Agreed. And maybe next episode we can look at a board that handled a similar situation well — to see the contrast. Lucas: That's a great idea. I'll dig into that for next time.